New biologic aims to tackle stubborn high triglycerides

NCT ID NCT07680829

Not yet recruiting Disease control Sponsor: Zhejiang Doer Biologics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This phase 3 trial tests an investigational injectable drug called DR10624 in adults with severe hypertriglyceridemia (very high blood fats) that remains high despite standard treatment. Participants continue their usual omega-3 therapy and receive weekly injections of DR10624 or a placebo. The study measures how much triglycerides drop over 26 weeks and checks safety and other lipid levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DR10624 (injectable biologic) plus icosapent ethyl (oral omega-3)
What this could lead to: If successful, this could offer a new add-on treatment option for people with severe high triglycerides that are not controlled by current therapy.
What could go wrong: This is a phase 3 trial, but the drug is still investigational. It may not prove effective or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE HYPERTRIGLYCERIDEMIA

Contacts and locations

Locations

Peking University First Hospital

Beijing, China
Peking University People's Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.